David A. Siegel Aerovate Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$2.37 - $2.7 $327,534 - $373,140	138,200 Added 89.97%	291,800 $732,000
Q4 2024 Feb 14, 2025	BUY	$1.99 - $2.79 $84,973 - $119,133	42,700 Added 38.5%	153,600 $407,000
Q3 2024 Nov 14, 2024	BUY	$1.61 - $2.09 $66,171 - $85,899	41,100 Added 58.88%	110,900 $231,000
Q2 2024 Aug 14, 2024	BUY	$1.41 - $30.75 $87,420 - $1.91 Million	62,000 Added 794.87%	69,800 $115,000
Q1 2024 May 15, 2024	BUY	$17.68 - $29.57 $137,904 - $230,646	7,800 New	7,800 $230,000

1.63M

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $65.5M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.